Baili Tianheng (688506.SH): GNC-077 monoclonal antibody injection for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notification.

22/09/2024

Baili Tianheng (688506.SH) announced that the company has recently received approval from the National Medical Products Administration (NMPA)...

Baoli Tianheng (688506.SH) announced that the company recently received the official approval letter for the clinical trial of the company's independently developed innovative biopharmaceutical GNC-077 from the National Medical Products Administration (NMPA). According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, the clinical trial application for GNC-077 multi-specific antibody injection, which was accepted on July 16, 2024, meets the relevant requirements for drug registration, and the company has been authorized to conduct clinical trials for late-stage solid tumors.

HK Stock Market Move | AKESO (09926) rose more than 7% in early trading. The company's first dual-immune ADC drug AK146D1 entered clinical trials.

HK Stock Market Move | SIMCERE PHARMA(02096) rises more than 3%. The new generation of anti-VEGF monoclonal antibody "Suvixitumab monoclonal antibody" has been approved for listing.

HK Stock Market Move | Gambling stocks continue to rise, Macau's gambling revenue in June exceeded expectations, Citigroup expects the growth momentum to continue in the second half of the year.

HK Stock Market Move | AKESO (09926) rose more than 7% in early trading. The company's first dual-immune ADC drug AK146D1 entered clinical trials.

HK Stock Market Move | SIMCERE PHARMA(02096) rises more than 3%. The new generation of anti-VEGF monoclonal antibody "Suvixitumab monoclonal antibody" has been approved for listing.

HK Stock Market Move | Gambling stocks continue to rise, Macau's gambling revenue in June exceeded expectations, Citigroup expects the growth momentum to continue in the second half of the year.